AU2002329061A1 - Gene and protein relating to hepatocellular carcinoma - Google Patents

Gene and protein relating to hepatocellular carcinoma

Info

Publication number
AU2002329061A1
AU2002329061A1 AU2002329061A AU2002329061A AU2002329061A1 AU 2002329061 A1 AU2002329061 A1 AU 2002329061A1 AU 2002329061 A AU2002329061 A AU 2002329061A AU 2002329061 A AU2002329061 A AU 2002329061A AU 2002329061 A1 AU2002329061 A1 AU 2002329061A1
Authority
AU
Australia
Prior art keywords
gene
hepatocellular carcinoma
protein relating
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002329061A
Other languages
English (en)
Inventor
Yoichi Furukawa
Yusuke Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
University of Tokyo NUC
Original Assignee
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2399569 external-priority patent/CA2399569A1/en
Application filed by Oncotherapy Science Inc, University of Tokyo NUC filed Critical Oncotherapy Science Inc
Publication of AU2002329061A1 publication Critical patent/AU2002329061A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002329061A 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma Abandoned AU2002329061A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32426101P 2001-09-25 2001-09-25
US60/324,261 2001-09-25
US39166602P 2002-06-26 2002-06-26
US60/391,666 2002-06-26
CA 2399569 CA2399569A1 (en) 2001-09-25 2002-08-23 Diagnostic markers and drug targets for treatment of cancer
CA2,399,569 2002-08-23
PCT/JP2002/009876 WO2003027143A2 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
AU2002329061A1 true AU2002329061A1 (en) 2003-04-07

Family

ID=27171637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002329061A Abandoned AU2002329061A1 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Country Status (9)

Country Link
US (3) US7767392B2 (https=)
EP (1) EP1430152B1 (https=)
JP (1) JP4353798B2 (https=)
CN (1) CN1628179B (https=)
AT (1) ATE356223T1 (https=)
AU (1) AU2002329061A1 (https=)
DE (1) DE60218710T2 (https=)
ES (1) ES2283592T3 (https=)
WO (1) WO2003027143A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1628179B (zh) 2001-09-25 2011-04-20 肿瘤疗法科学股份有限公司 肝细胞癌的检测
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
DE602004032114D1 (de) * 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
CN1890382A (zh) * 2003-09-24 2007-01-03 肿瘤疗法科学股份有限公司 检测、诊断和治疗肝细胞癌(hcc)的方法
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20060189560A1 (en) * 2005-01-27 2006-08-24 Ajit Kumar Molecular method to augment RNA mediated gene silencing
WO2006092958A1 (en) * 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Breast cancer related gene znfn3a1
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
EP2171082B1 (en) 2007-06-14 2012-11-28 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3
CN102356316B (zh) 2009-03-05 2015-07-08 独立行政法人产业技术综合研究所 肝内胆管癌的检出、辨别方法
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2785870B1 (en) 2011-12-02 2017-05-03 OncoTherapy Science, Inc. Smyd2 as a target gene for cancer therapy and diagnosis
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039200A1 (en) 1998-01-29 1999-08-05 Thomas Jefferson University Molecular markers for diagnosing hepatocellular carcinoma
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000017355A2 (en) 1998-09-18 2000-03-30 Incyte Pharmaceuticals, Inc. Human cytoskeleton associated proteins
JP2003521231A (ja) * 1999-01-29 2003-07-15 インサイト・ファーマスーティカルズ・インコーポレイテッド 核酸結合タンパク質
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001029221A2 (en) 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
AU783762B2 (en) 1999-12-23 2005-12-01 Arca Biopharma, Inc. Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
EP1591448A3 (en) 2000-04-18 2006-01-11 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス, インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
GB0111218D0 (en) 2001-05-08 2001-06-27 Cancer Res Ventures Ltd Assays methods and means
US6989245B2 (en) 2001-05-11 2006-01-24 The Burnham Institute Screening, diagnostic and therapeutic methods relating to RIZ
DK2280070T3 (en) 2001-07-23 2015-08-24 Univ Leland Stanford Junior Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
CN1628179B (zh) * 2001-09-25 2011-04-20 肿瘤疗法科学股份有限公司 肝细胞癌的检测
US8003315B2 (en) * 2001-12-13 2011-08-23 Exelixis, Inc. TAOJIKs as modifiers of the beta-catenin pathway and methods of use
DE602004032114D1 (de) 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
WO2006092958A1 (en) 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Breast cancer related gene znfn3a1
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
EP2171082B1 (en) 2007-06-14 2012-11-28 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3

Also Published As

Publication number Publication date
WO2003027143A3 (en) 2003-10-30
US20040235018A1 (en) 2004-11-25
JP4353798B2 (ja) 2009-10-28
CN1628179B (zh) 2011-04-20
WO2003027143A2 (en) 2003-04-03
DE60218710D1 (de) 2007-04-19
US7767392B2 (en) 2010-08-03
EP1430152A2 (en) 2004-06-23
US20120149762A1 (en) 2012-06-14
EP1430152B1 (en) 2007-03-07
US8148080B2 (en) 2012-04-03
ATE356223T1 (de) 2007-03-15
US20100248240A1 (en) 2010-09-30
DE60218710T2 (de) 2007-12-06
CN1628179A (zh) 2005-06-15
JP2005511023A (ja) 2005-04-28
ES2283592T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
AU2002329061A1 (en) Gene and protein relating to hepatocellular carcinoma
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
EP2230319A3 (en) Gene expression markers for breast cancer prognosis
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
LTPA2015049I1 (lt) Žpv 45 l1 optimizuota ekspresija mielėse
ZA200405388B (en) Binding proteins as biosensors
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
EP1678315A4 (en) ZINC FINGER PROTEINS FROM GENETIC GENE FOR REGULATING GENE EXPRESSION
GB2406169B (en) Methods and compositions relating to labeled rna molecules that reduce gene expression
WO2005049075A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005044792A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2004013307A3 (en) Compounds for targeting hepatocytes
AU2003240221A1 (en) Genes and polypeptides relating to hepatocellular or colorectal carcinoma
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004024064A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1708677A4 (en) COSMETIC COMPOSITION CONTAINING A PROTEIN AND AN ENZYME INHIBITOR
AU2002324649A1 (en) Haplotype map of the human genome and uses therefor
AU2003262727A1 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
AU2003243381A1 (en) Variants of antithrombin iii
AU2003258127A1 (en) Compositions and methods relating to ovarian specific genes and proteins
AU1539801A (en) Transcription factors containing two potential dna binding motifs
AU2002362414A1 (en) Novel molecules of the hkid-1-related protein family and uses thereof
WO2004006864A3 (en) Methods and compositions for the enhancement of wound healing
EP1774966A4 (en) MEANS TO INHIBIT THE USE AND PROGRESS OF LIVER CANCER IN PATIENTS WITH HEPATITIS C-VIRUS POSITIVE LIVER CIRR

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase